Europe Pharmacovigilance And Drug Safety Software Market Scope And Analysis

  • Report Code : TIPRE00022771
  • Category : Technology, Media and Telecommunications
  • Status : Published
  • No. of Pages : 205
Buy Now

Europe Pharmacovigilance and Drug Safety Software Market Scope 2031

Buy Now

Europe Pharmacovigilance and Drug Safety Software Market Report Europe Pharmacovigilance and Drug Safety Software Market Size and Share Europe Pharmacovigilance and Drug Safety Software Market Scope and Analysis

Europe Pharmacovigilance and Drug Safety Software Market Report Scope

Report Attribute Details
Market size in 2023 US$ 52.37 Million
Market Size by 2031 US$ 84.66 Million
Global CAGR (2023 - 2031) 6.2%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Offering
  • Software
  • Services
By Deployment
  • Cloud
  • On Premises
By Enterprise Size
  • Large Enterprises
  • SMEs
By Form
  • Standard
  • Customized
Regions and Countries Covered Europe
  • France
  • Germany
  • Italy
  • Spain
  • the UK
  • the Rest of Europe
Market leaders and key company profiles
  • ArisEurope
  • ICON plc Syneos Health
  • Accenture
  • IQVIA
  • Genpact
  • Cognizant
  • Paraxel International Corporation
  • Laboratory Corporation of America Holdings
  • Max Application
  • Clinevo Technologies

    • Europe Pharmacovigilance and Drug Safety Software Market News and Recent Developments

    The Europe pharmacovigilance and drug safety software market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Europe pharmacovigilance and drug safety software market are listed below:

    • ArisGlobal—a market leader in global drug development technology solutions, announced that Medac, a German-based pharmaceutical manufacturer specializing in the fields of oncology and hematology, urology, and autoimmune diseases—chose LifeSphere Safety to modernize its drug safety processes. Precise, patient- and population-specific analysis is crucial for minimizing treatment risks for patients, which supports the best possible treatment outcome. (Source: ArisGlobal, Press Release, May 2023)
    • IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced a strategic collaboration with Argenx to advance treatment to patients suffering from rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions. (Source: IQVIA, Press Release, January 2023)

    Europe Pharmacovigilance and Drug Safety Software Market Report Coverage and Deliverables

    The "Europe Pharmacovigilance and Drug Safety Software Market Size and Forecast (2021–2031)" provides a detailed analysis of the market covering the areas mentioned below:

    • Europe pharmacovigilance and drug safety software market size and forecast at country levels for all the key market segments covered under the scope
    • Europe pharmacovigilance and drug safety software market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Europe pharmacovigilance and drug safety software market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Europe pharmacovigilance and drug safety software market
    • Detailed company profiles